![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Emergent BioSolutions to Develop Two COVID-19 Treatments
Emergent BioSolutions to Develop Two COVID-19 Treatments
![](https://www.fdanews.com/ext/resources/test/Device_Images6/emergent-biosolutions-logo.gif?t=1578316219&width=261)
Maryland-based Emergent BioSolutions announced that it is developing two plasma- based product candidates to treat and prevent COVID-19.
COVID-HIG will be manufactured from human plasma with antibodies to the virus as a potential treatment for severe hospitalized patients and protection for at-risk individuals.
COVID-EIG will use plasma of immunized horses with antibodies to the virus, which will be used as a potential treatment for severe hospitalized patients.
Upcoming Events
-
18Jul
-
21Oct